| ID | 1363 |
| Name of the vaccine | CombAct-HIB |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | up to 3 days |
| Description of the vaccine | DTwP used to reconstitute freeze-dried Hib vaccine. |
| Name of the manufacturer | Sanofi Pasteur, a Sanofi Company |
| Name of the manufacturing country | South Africa |
| Year of manufacture | 2009 |
| Clinical Phase status | Clinical - Phase 3 |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | NA
|
| Vaccine formulation | Liquid suspension |
| Dosage | Primary series of 3 doses and booster dose at 15 to 18 months. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For diphtheria, pertussis, polio, hepatitis B and Hib. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 31444785 |
| Clinical trial number | NCT00362336 |
| Reference | https://www.tabletwise.net/southafrica/combact-hib-vaccine |
| Other name | NA |
| Additional Links | NA
|